Drug Trial Radar · NCT04326374
Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Mar 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 30, 2019
Primary completion
Apr 2022
Study completion Apr 2022
Sponsor
- Lead sponsor
- Visen Pharmaceuticals (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Ascendis Pharma A/S
- First posted
- Mar 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted in China only. The purpose is to demonstrate the efficacy and safety of once weekly dosing of TransCon hGH, a long-acting growth hormone product, compare to once-daily dosing of human growth hormone (hGH) after 52 weeks of treatment in prepubertal children with growth hormone deficiency (GHD).
Conditions
- Growth Hormone Deficiency
- Endocrine System Diseases
- Hormones
- Pituitary Diseases
- Pituitary Disease, Anterior
Interventions
TransCon hGHDrug
Once weekly subcutaneous injection
daily hGHDrug
Once daily subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized height velocity(AHV) at Week 52Time frame: 52 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.